Current Issues in Medicine
Biochemistry, Genomics, Physiology and Pharmacology
- Available for pre-order. Item will ship after June 30, 2021
The pace and sophistication of advances in medicine in the past two decades have necessitated a growing need for a comprehensive reference that highlights current issues in medicine. Each volume in the Current Issues in Medicine series is a stand‐alone text that provides a broad survey of various critical topics—all accomplished in a user-friendly yet interconnected format. The series not only highlights current advances but also explores related topics such as translational medicine, regulatory science, neglected diseases, global pandemics, patent law, immunotoxicology, ethics, theranostics, big data, artificial intelligence, novel imaging tools, combination drug products, and novel therapies. While bridging the gap between basic research, medicine, engineering, FDA law, intellectual property law, and regulatory science, the series provides a thorough understanding of medicine's potential to address health problems from both the patient’s and the provider's perspectives in a healthcare setting. The range of topics covered, and the expertise of the contributing authors accurately reflect the rapidly evolving areas within medicine—from basic medical sciences to clinical specialties. Current Issues in Medicine is essential reading for physicians, medical students, nurses, fellows, residents, undergraduate and graduate students, educators, policymakers, and biomedical researchers. The book’s multidisciplinary approach makes it a valuable reference resource for the pharmaceutical industry, academia, and governments globally. However, unlike other series on medicine or medical textbooks, this series focuses on current trends, perspectives, and issues in medicine that are central to healthcare delivery in the 21st century.Volumes 1 and 2 in this series are focused on the current issues in basic medical science, subjects that are fundamental to the practice of medicine. These subjects are traditionally taught in the first two years of medical school that precede clinical instruction and training. They provide a core of basic knowledge critical to the success in clinical medicine during rotations through surgery, internal medicine, and the other specialties of medicine. Obviously, knowledge gleaned from these subjects leads to better ways to predict, prevent, diagnose, and treat disease. Specifically, volume 1 covers biochemistry, genomics, physiology, and pharmacology. Clinical specialties are covered in Volume 3. Volume 4 is directed towards diagnosis and imaging techniques, volume 5 focuses on drug delivery, and volume 6 highlights novel therapeutics and clinical applications.
Table of Contents
BIOCHEMISTRY AND GENOMICS
Role of Engineered Proteins as Therapeutic Formulations
Khushboo Gulati and Krishna Mohan Poluri
How Physical and Chemical Information Predicts the Action of Molecules: A Historical Overview
Myron L. Toews, JoEllyn M. McMillan, and David B. Bylund
Links between Integrin αvβ3 and COVID-19: Impact on Vascular and thrombotic Risk
Marwa S. Hamza and Shaker A. Mousa
Aptamers, the Nucleic Acid Antibodies, in Cancer Therapy
Zhaoying Fu and Jim Xiang
Identifying Genetic Markers Associated with Susceptibility to Cardiovascular Diseases
Hitesh Shukla, Jessica Louise Mason, and Abdullah Sabyah
Production and Application of Multicistronic Constructs for Various Human Disease Therapies
Alisa A. Shaimardanova, Daria S. Chulpanova, Kristina V. Kitaeva, Ilmira I. Abdrakhmanova, Vladislav M. Chernov, Catrin S. Rutland, Albert A. Rizvanov, and Valeriya V. Solovyeva
The Nuclear Lamina: Protein Accumulation and Disease
Carla Almendáriz-Palacios, Zoe E. Gillespie, Matthew Janzen, Valeria Martinez, Joanna M. Bridger, Troy A. A. Harkness, Darrell D. Mousseau, and Christopher H. Eskiw
Do Post-Translational Modifications Influence Protein Aggregation in Neurodegenerative Diseases: A Systematic Review
Larissa-Nele Schaffert and Wayne G. Carter
DNA Damage/Repair Management in Cancers
Jehad F. Alhmoud, John F. Woolley, Ala-Eddin Al Moustafa, and Mohammed Imad Malki
Advancing Clinical Cohort Selection with Genomics Analysis on a Distributed Platform
Jaclyn M. Smith, Melvin Lathara, Hollis Wright, Brian Hill, Nalini Ganapati,Ganapati Srinivasa, Christopher T. Denny
Pharmacogenomics of Tamoxifen
Nanocrystals: The Universal Formulation Principle to Improve the Bioactivity of Poorly Soluble Actives
Ralph W. Eckert, Steffen F. Hartmann, Daniel Knoth, Olga Pelikh, Rainer H. Müller, and Cornelia M. Keck
Trends towards Biomimicry in Theranostics
Michael Evangelopoulos, Alessandro Parodi, Jonathan O. Martinez, IDand Ennio Tasciotti
PHYSIOLOGY AND PHARMACOLOGY
Quantitative EEG Features Selection in the Classification of Attention and Response Control in the Children and Adolescents with Attention Deficit Hyperactivity Disorder
Azadeh Bashiri, Leila Shahmoradi, Hamid Beigy, Behrouz A Savareh, Masood Nosratabadi, Sharareh R. N. Kalhori, and Marjan Ghazisaeedi
Apoptotic Bodies: Particular Extracellular Vesicles Involved in Intercellular Communication
Michela Battistelli and Elisabetta Falcieri
Circulating Tumor Cells and Personalized Medicine
Jin Sun Lee, Mark Jesus M. Magbanua, Marc R. Jabon, and John W. Park
Pathology in the Era of Personalized Medicine
Hye Seung Lee
Speech Intelligibility During Clinical and Low Frequency
John J. Sidtis, Diana Van Lancker Sidtis, Ritesh Ramdhani, and Michele Tagliati
Physiological Renormalization Using Systems Therapeutics
Pathology Is Always Around Us: Apophenia in Pathology, a Remarkable Unreported Phenomenon
Ahmed S. Sultan and Maryam Jessri
The Secrets of the Mediterranean Diet. Does [Only] Olive Oil Matter?
Alessandra Mazzocchi, Ludovica Leone, Carlo Agostoni, and Isabella Pali-Schöll
Relationship between Diet, Microbiota, and Healthy Aging
Elisa Sanchez-Morate, Lucia Gimeno-Mallench, Kristine Stromsnes, and Jorge Sanz-Ros, Aurora Román-Domínguez, Sergi Parejo-Pedrajas, Marta Inglés, Gloria Olaso, Juan Gambini, and Cristina Mas-Bargues
Bridging for Drug-Device and Biologic-Device Combination Products: Guidance for Industry
U.S. Department of Health and Human Services, Food and Drug Administration, USA
Current Methodologies Utilized in the Conduct of Randomized Clinical Trials
Marina A. Malikova
Raj Bawa, MS, PhD, is president of Bawa Biotech LLC, a biotech/pharma consultancy and patent law firm based in Ashburn, Virginia, USA, that he founded in 2002. Trained as a biochemist and microbiologist, he is an inventor, entrepreneur, professor, and registered patent agent licensed to practice before the US Patent & Trademark Office. He is currently a scientific advisor to Teva Pharmaceutical Industries, Ltd. (Israel), a visiting research scholar at the Pharmaceutical Research Institute of Albany College of Pharmacy (Albany, New York), and vice president and chief intellectual property officer at Guanine, Inc. (Rensselaer, New York). He has previously served as a principal investigator of National Cancer Institute SBIRs and continues to be a scientific reviewer for both the NIH and NSF. He recently (2017–2019) served as principal investigator of a CDC grant to develop an assay for Carbapenem-resistant Enterobacteriaceae. Since 2004, he has been an adjunct professor in the biology department and the Extended Learning Institute of Northern Virginia Community College (Annandale, Virginia), where he also teaches human anatomy and physiology to pre-nursing students. In the 1990s, Dr. Bawa held various positions at the US Patent & Trademark Office, including primary patent examiner from 1996–2002. Previously, he was an adjunct professor at Rensselaer Polytechnic Institute in Troy, New York from 1998–2018, where he received his doctoral degree in three years (biophysics/biochemistry).
Dr. Bawa is a life member of Sigma Xi, co-chair of the nanotech and precision medicine committees of the American Bar Association (2015–2021), and founding director of the American Society for Nanomedicine (founded in 2008). He has authored over 100 publications, co-edited 9 texts, and serves on the editorial boards of numerous peer-reviewed journals, including serving as an associate editor of Nanomedicine (Elsevier). Some of Dr. Bawa’s awards include the Innovations Prize from the Institution of Mechanical Engineers, UK (2008); Appreciation Award from the US Undersecretary of Commerce, Washington, DC (2001); the Key Award from Rensselaer’s Office of Alumni Relations (2005); and Lifetime Achievement Award from the American Society for Nanomedicine (2014).
Esther H. Chang, PhD, is a member of the Departments of Oncology and Otolaryngology at the Lombardi Comprehensive Cancer Center of Georgetown University Medical Center, USA. She previously held positions at the National Cancer Institute, Stanford University, and the Uniformed Services University of Health Sciences. She is president of the American Society for Nanomedicine and an executive board member of the International Society for Nanomedicine. Dr. Chang is the founding scientist of and senior consultant for SynerGene Therapeutics, Inc., a privately held company that has five ongoing clinical trials for two distinct nanomedicines. She has over 140 scientific publications and has served as a member of a number of scientific advisory boards for NCI, NASA, the US Military Cancer Institute, and the Department of Energy. Dr. Chang’s research effort focuses primarily on the molecular mechanisms of carcinogenesis and in translating this basic information into new clinical modalities. She has been a contributor in the understanding of oncogenes and tumor suppressor genes. She has also contributed to the understanding of the molecular basis of resistance to radiation and chemotherapy. She is the inventor/co-inventor of 115 issued patents (50 applications being prosecuted) surrounding a tumor-targeting nanodelivery platform being developed by SynerGene. This nanodelivery system represents a broad platform nanotechnology in that the payload for delivery can include gene therapy, siRNAs/miRNAs, antisense oligonucleotides, imaging agents, and chemotherapeutic agents.
Gerald F. Audette, PhD, is associate dean of faculty in the Faculty of Science, an associate professor of chemistry, and member of the Centre for Research on Biomolecular Interactions at York University, Canada. His research focuses on the correlation between protein structure and biological activity of proteins involved in bacterial conjugation, in particular, the type 4 secretion system from the conjugative F-plasmid of Escherichia coli. In addition, his research targets the type IV pilins and associated assembly systems from several bacterial pathogens and is exploring the adaptation of these protein systems for applications in bionanotechnology and nanomedicine. Dr. Audette is the co-editor of volumes 1–4 of the Jenny Stanford Series on Nanomedicine and is a subject editor of structural chemistry and crystallography for the journal FACETS.
Anil R. Diwan, PhD, is president and chairman of NanoViricides, Inc., a publicly traded company dedicated to advancing antiviral applications of a novel nanomedicines platform with the potential for creating drugs that the virus cannot escape by virtue of genomic changes, (mutations, recombinations, re-assortments) that are common in the virus world. He founded his own private company and began working in nanomedicines circa 1992. There he invented ""TheraCour®"" polymeric micelle zip-code-like targeting and encapsulating drug delivery platform. With his colleagues at AllExcel, Inc., he has also co-developed a novel cell therapy that promises to be a cure for Parkinson’s Disease. Dr. Diwan received his first US patent in nanomedicines in 2004. Further advancements have already resulted in three international PCT applications that have matured into a number of patents worldwide. Dr. Diwan co-founded NanoViricides, Inc., in 2005 and played a key role in its up-listing NYSE-American exchange in 2013. He has been instrumental in raising over $100 million at NanoViricides since founding it. He was also instrumental in the design and architecture of the new NanoViricides campus in Shelton, CT with discovery-to-cGMP-manufacture capabilities under one roof. Dr. Diwan was recognized as ""2014 Researcher of the Year"" by BusinessNewHaven and NewHaven Register group, which provides annual recognitions for outstanding individuals in Connecticut state.
Dr. Diwan obtained his BS in chemical engineering from the Indian Institute of Technology, Bombay, India, in 1980. Acceptance to the Indian Institute of Technology is based on the ultra-competitive Joint Entrance Examination. Dr. Diwan stood 9th nationally in this examination. Following his undergraduate degree, he obtained his PhD in (bio)chemical engineering in 1986 from Rice University, Houston, USA.
Saadia A. Faiz, MD, currently practices at the University of Texas MD Anderson Cancer Center as a pulmonary and sleep specialist in cancer medicine. She is a professor of pulmonary medicine in the Division of Internal Medicine. She is board certified by the American Board of Internal Medicine in internal medicine, critical care, pulmonary and sleep medicine. Dr. Faiz is an active member of the American College of Chest Physicians and serves on the 2020 Scientific Program Executive Committee, the Clinical Pulmonary Network Steering Committee, and Educator Development Subcommittee. Her research interests include pulmonary manifestation of cancer, pleural disease in hematologic malignancies, pulmonary hypertension in cancer and sleep and cancer. She also dedicated a significant amount of time to trainee education specifically using simulation for procedural education. She founded and is the director for the Southwest Regional Boot Camp for First Year Pulmonary and Critical Care Fellows, and she serves as an associate program director for the McGovern Medical School at UTHealth PCCM fellowship. She also serves as a faculty instructor for the CHEST Live Learning Pleural Procedures course and at the annual CHEST Fellows course.